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IntroductIon
Survival paradoxes are commonly observed 
in the literature. This phenomenon describes 
the association of certain risk factors with 
negative outcomes in the general population 
and the opposite effect in certain subpopu-
lations and vice versa. Overall, the field is 
poorly understood. The counter-intuitive 
findings reported in the literature have 
contributed to confusion among clinicians 
regarding the appropriate treatment of 
conventional risk factors in patients with 
chronic diseases. Below we review two such 
paradoxes in kidney and cardiovascular 
disease epidemiology and discuss possible 
explanations of these findings.
SurvIval advantage among Black 
HemodIalySIS PatIentS
Despite racial disparities among blacks in 
socioeconomic position, education, life-
style factors, comorbid conditions, access 
to medical care, and utilization of health 
services, a reverse survival advantage is seen 
in hemodialysis patients. For example, con-
ventional cardiovascular risk factors such 
as black race, hypercholesterolemia, hyper-
tension, and obesity are associated with 
increased survival among hemodialysis 
patients (1).
One of the first comprehensive studies 
to report a survival paradox among hemo-
dialysis patients was conducted in eastern 
Michigan among 594 diabetic end-stage 
renal disease (ESRD) patients (2). Risk 
of death was nearly 45% [Hazard Ratio 
(HR) = 0.55, 95% Confidence Interval 
(CI) = 0.44–0.69] lower in black hemodi-
alysis patients compared with white hemo-
dialysis patients after adjusting for factors 
related to survival in their database (type of 
diabetes, comorbid conditions, and demo-
graphic factors) (2). This study was consist-
ent with the point prevalence results from 
the U.S. Renal Data System report showing 
a lower annual adjusted (age, gender, race, 
primary diagnosis, and vintage) death rate 
(per 1000 patient years) of 187 for black 
hemodialysis patients compared with 223 
for white hemodialysis patients (3). Another 
analysis of the U.S. Renal Data System data-
base reported that the survival paradox 
persisted after adjustment for case-mixed 
differences [Relative Risk (RR) = 0.78, 
95% CI = 0.71–0.86], transplantation 
rates (RR = 0.83, 95% CI = 0.75–0.91), 
withdrawal from dialysis (RR = 0.81, 95% 
CI = 0.73–0.90), and initial treatment mor-
tality (RR = 0.79, 95% CI = 0.71–0.87) (4).
The survival advantage observed in the 
above studies, if not artifactual, may be due 
to differences in genetics, nutritional status, 
inflammation, and sensitivity to dialysis (5, 
6). However, results of the American arm of 
the first phase of the Dialysis Outcomes and 
Practice Patterns Study, a prospective obser-
vational study of 6677 patients between 1996 
and 2001, found that the cumulative adjust-
ment for laboratory (bicarbonate, calcium-
phosphorus product, ferritin, hemoglobin, 
potassium, transferrin saturation, and white 
blood cell count) and hemodialysis (treatment 
time, systolic blood pressure pre-dialysis, and 
ultrafiltration volume) measures, in a model 
that already adjusted for conventional car-
diovascular disease risk factors, resulted in a 
near null HR for race as a predictor of survival 
among hemodialysis patients (HR = 0.97, 
95% CI = 0.85–1.11) (7). Although the effect 
size was diminished in the latter study, it is 
unclear whether over-adjustment by factors 
in the causal pathway explains the result.
oBeSIty SurvIval advantage In 
cardIovaScular dISeaSe
Recently, several longitudinal studies 
have shown that obesity is associated 
with improved survival compared with 
normal weight individuals. Data from 
the PREMIER and TRIUMPH national 
 registries of patients hospitalized with acute 
myocardial infarction observed a decreased 
risk of mortality at 1 year among patients 
with body mass index (BMI) ≥ 35 kg/m2 
compared with normal weight  individuals 
(HR = 0.59, 95% CI = 0.37–0.91) (8). 
Patients from the APPROACH registry 
that received coronary artery bypass graft-
ing (CABG) for the treatment of coronary 
artery disease had a lower risk of mortality 
if their BMI ranged from 30.0 to 34.9 kg/
m2 compared with normal weight patients 
(HR = 0.75, 95% CI = 0.61–0.94) (9). 
Decreased HRs also were noted for BMI 
categories 25.0–29.9 kg/m2 (HR = 0.85), 
35.0–39.9 kg/m2 (HR = 0.89), and >40.0 kg/
m2 (0.77), although upper CIs spanned 
unity.
The so-called obesity paradox also has 
been reported in a national examination 
of 348,341 isolated CABG patients from 
the Society of Thoracic Surgeons Adult 
Cardiac Surgery Database demonstrating 
that high (BMI > 25 kg/m2) across postop-
erative time periods (30 days to > 2 years) 
was significantly associated with decreased 
mortality compared with normal weight 
individuals (p < 0.05) (10). However, the 
decreased effect sizes were nominal ranging 
from 0.79 to 0.94.
While the explanation for the obe-
sity paradox among patients with 
 cardiovascular disease is unknown, the 
results possibly may be attributable to 
 having better nutritional reserves to pro-
tect against mortality. Alternatively, treat-
ment and referral biases could account for 
these differences. Physicians may be more 
likely to refer obese patients for treatment 
since they are perceived to be a high-risk 
group for developing coronary artery 
disease.
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grand cHallenge
Reverse survival paradoxes may reflect 
the observational nature of epidemiologic 
studies. While such studies are excellent for 
the generation of hypotheses, they are una-
ble to prove causality. Whether the reverse 
epidemiologic effects are real or merely 
reflect the consequences of other under-
lying factors (e.g., residual confounding, 
violation of the independent censoring 
assumption, inappropriate adjustment, 
differential withdrawal from study par-
ticipation, or Simpson’s paradox) remains 
controversial, especially given the lack of 
convincing underlying pathophysiological 
evidence. Explaining survival paradoxes in 
the field of epidemiology remains a grand 
challenge for future researchers in this 
field.
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